EyePoint Pharmaceuticals (EYPT) Goldman Sachs 45th Annual Global Healthcare Conference summary

Pipeline and Clinical Development

• DURAVYU, a sustained-release intravitreal insert with vorolanib, is advancing to Phase 3 trials for wet AMD, with initiation expected in the second half of 2024 and topline data anticipated in 2026.

• Positive Phase 2 DAVIO 2 results in wet AMD showed non-inferiority to aflibercept, favorable safety, and significant reduction in treatment burden.

• DURAVYU is also being evaluated in NPDR (PAVIA) and DME (VERONA), with topline DME data expected Q1 2025.

• EYP-2301, a Tie-2 agonist in Durasert E, is in preclinical development for serious retinal diseases.

• Durasert technology enables safe, sustained intravitreal drug delivery, with both bioerodible and non-erodible formulations used in multiple FDA-approved products.

Product Mechanism and Differentiation

• DURAVYU blocks all VEGF receptors and PDGF, offering a new mechanism for VEGF-mediated diseases.

• The insert is injected in-office, is tiny, and settles out of the patient’s line of sight.

• Immediate drug release is achieved, with controlled, steady-state delivery and full matrix erosion over months.

• Product is shipped and stored at ambient temperature, unlike competitors.

• Patent protection extends to 2037, potentially 2042.

Clinical Trial Results and Safety

• DAVIO 2 Phase 2 trial in wet AMD met all primary and secondary endpoints, with both 2mg and 3mg DURAVYU arms showing non-inferior BCVA change versus aflibercept.

• DURAVYU reduced treatment burden by up to 89%, with nearly two-thirds of eyes supplement-free for six months after a single injection.

• No DURAVYU-related serious adverse events observed across 170 patients; low discontinuation rate (4%).

• Subgroup analysis showed unsupplemented DURAVYU eyes had equal or better visual acuity than EYLEA.

• Anatomic control was stable in DURAVYU arms, while EYLEA showed sawtooth OCT pattern.